Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

CemiplimAb Survivorship Epidemiology

Active, not recruiting

Conditions: Cutaneous Squamous Cell Carcinoma
Basal Cell Carcinoma

Interventions: Drug: cemiplimab

First Posted Date: 2019-02-11

Last Posted Date: 2023-10-30

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 287

Registration Number: NCT03836105

Locations: 🇺🇸
Lahey Hospital & Medical Center, Burlington, Massachusetts, United States
🇺🇸
Harbor-UCLA/LA Biomedical Research Institute, Los Angeles, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 44 locations

Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy

Phase 2

Completed

Conditions: Peanut Allergy

Interventions: Drug: Dupilumab

First Posted Date: 2019-01-04

Last Posted Date: 2022-05-19

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT03793608

Locations: 🇨🇦
Regeneron Investigational Site, Montreal, Quebec, Canada

Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe

Phase 4

Completed

Conditions: Chorioretinal Vascular Disease

Interventions: Drug: Intravitreal Aflibercept Injection (IAI)

First Posted Date: 2018-12-07

Last Posted Date: 2021-09-16

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 65

Registration Number: NCT03767738

Locations: 🇺🇸
Regeneron Study Site, The Woodlands, Texas, United States

Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Linvoseltamab

First Posted Date: 2018-12-03

Last Posted Date: 2025-05-15

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 387

Registration Number: NCT03761108

Locations: 🇺🇸
Indiana University_Michigan Street, Indianapolis, Indiana, United States
🇯🇵
Keio University Hospital, Tokyo, Japan
🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States

and more 38 locations

Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies

Phase 1

Terminated

Conditions: Advanced PD-L1 Positive Malignancies

Interventions: Drug: 89Zr˗DFO˗REGN3504

First Posted Date: 2018-11-20

Last Posted Date: 2022-02-23

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 2

Registration Number: NCT03746704

Locations: 🇺🇸
Regeneron Study Site, New York, New York, United States

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Phase 2

Terminated

Conditions: Atopic Dermatitis

Interventions: Drug: REGN3500
Drug: REGN3500-Matching Placebo

First Posted Date: 2018-11-13

Last Posted Date: 2022-06-10

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 129

Registration Number: NCT03738423

Locations: 🇬🇧
Regeneron Study Site, Sheffield, United Kingdom

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Phase 2

Terminated

Conditions: Atopic Dermatitis

Interventions: Drug: REGN3500
Drug: Dupilumab
Drug: REGN3500 + Dupilumab Combo
Drug: Placebo

First Posted Date: 2018-11-09

Last Posted Date: 2021-11-01

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 206

Registration Number: NCT03736967

Locations: 🇪🇸
Regeneron Research Site, Santiago de Compostela, Spain

Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

Phase 2

Withdrawn

Conditions: Sporadic Inclusion Body Myositis

Interventions: Drug: REGN2477+REGN1033
Drug: Matching placebo

First Posted Date: 2018-10-18

Last Posted Date: 2019-04-29

Lead Sponsor: Regeneron Pharmaceuticals

Registration Number: NCT03710941

Long Term Safety Study of PRALUENT

Phase 4

Terminated

Conditions: Heterozygous Familial Hypercholesterolemia
Non-familial Hypercholesterolemia

Interventions: Drug: Praluent

First Posted Date: 2018-10-03

Last Posted Date: 2021-06-15

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 1389

Registration Number: NCT03694197

Locations: 🇺🇦
Regeneron Research Site, Vinnytsya, Ukraine
🇷🇺
Regeneron Research Site 2, Yaroslavl, Russian Federation
🇺🇦
Regeneron Research Site #2, Kyiv, Ukraine

and more 2 locations

Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

Phase 2

Completed

Conditions: Osteoarthritis, Hip
Osteoarthritis, Knee

Interventions: Drug: Fasinumab
Other: Placebo

First Posted Date: 2018-10-02

Last Posted Date: 2023-03-01

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 180

Registration Number: NCT03691974

Locations: 🇬🇧
Regulatory Study Site, London, United Kingdom
🇬🇧
Regeneron Study Site, Waterloo, United Kingdom

Home Terms & Conditions Privacy Policy